Kiromic BioPharma will pay no fine to the Securities and Exchange Commission (SEC) after self-reporting that it failed to disclose material information about two cancer drugs to investors.

Learn More
Already a member? Sign in to an existing account.

Aaron Nicodemus is the Editor-in-Chief of Compliance Week. He previously worked as a reporter for Bloomberg Law and as business editor at the Telegram & Gazette in Worcester, Mass. Email: aaron.nicodemus@complianceweek.com LinkedIn:...